Download PDF

1. Company Snapshot

1.a. Company Description

Thermo Fisher Scientific Inc.provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally.The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.


Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories.The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products.Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research.


It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD.Thermo Fisher Scientific Inc.was founded in 1956 and is headquartered in Waltham, Massachusetts.

Show Full description

1.b. Last Insights on TMO

Thermo Fisher Scientific Inc.'s recent performance was negatively impacted by growth concerns and mixed segment performance. Despite beating Q1 EPS and revenue estimates, investors weighed stronger-than-expected quarterly profit against muted underlying growth and a cautious outlook. The company's valuation multiples appear stretched, and several institutional investors, including Consolidated Investment Group LLC and Baxter Bros Inc., have reduced their holdings. Additionally, some analysts consider the stock overvalued relative to its growth outlook.

1.c. Company Highlights

2. Thermo Fisher Rides Q1 Momentum, Raises Full‑Year Outlook

Thermo Fisher Scientific closed the first quarter on a high note, reporting revenue of $11.01 billion, up 6% YoY, and adjusted operating income of $2.40 billion, a 6% lift that drove the adjusted operating margin to 21.8%. The company’s adjusted EPS came in at $5.44, surpassing analyst estimates of $5.25, a testament to disciplined cost control and productive sales execution. As CFO Jim Meyer highlighted, “We delivered a strong quarter with excellent execution by the team.”

Publication Date: Apr -24

📋 Highlights
  • Revenue Growth: Q1 revenue increased 6% to $11.01 billion, with adjusted operating income up 6% to $2.4 billion and a 21.8% adjusted operating margin.
  • Full-Year Guidance Raised: Revenue guidance raised to $47.3–$48.1 billion (6–8% growth over 2025), and adjusted EPS guidance set at $24.64–$25.12 (8–10% growth).
  • Clario Acquisition Impact: The acquisition added $900 million in revenue and $0.32 of adjusted EPS net of financing costs, enhancing clinical research capabilities.
  • Capital Deployment: $3 billion in share repurchases and a 10% dividend increase, reflecting disciplined capital returns to shareholders.
  • Pharma/Biotech Momentum: Strong growth in bioproduction and clinical research, with 6% adjusted operating income growth in the clinical research segment and 3–4% organic revenue growth expected for 2026.

Revenue Growth

Revenue climbed 6% to $11.01 billion, reflecting solid demand across the pharmaceutical, biotech, and diagnostics end markets. The company added $900 million in revenue from the newly acquired Clario, underscoring the strategic fit and immediate contribution of the digital endpoint data platform.

Margin Performance

Adjusted operating margin improved to 21.8%, driven by higher productivity and efficient mix management. While the margin edged down 10 basis points from the prior year quarter, the company offset this through favorable pricing and cost synergies from the Clario integration.

Guidance Update

Thermo Fisher lifted its full‑year revenue guidance to $47.3 billion–$48.1 billion, a 6%–8% increase over 2025, and adjusted EPS to $24.64–$25.12, representing 8%–10% growth. The update incorporates a 3%–4% organic revenue growth assumption and the $0.32 adjusted EPS contribution from Clario.

Capital Deployment

Capital deployment remains disciplined: the company completed the Clario acquisition, repurchased $3 billion of shares, and raised its dividend by 10%. These actions reinforce shareholder value while maintaining a healthy balance sheet, with Net Debt/EBITDA at 3.58.

End‑Market Outlook

Pharma and biotech markets continue to expand, buoyed by bioproduction momentum and clinical research demand. Diagnostics, however, lagged slightly, reflecting softer end‑market conditions. The company anticipates stronger growth in its Pharma Services business in the second half of the year.

AI, Innovation & Inflation

Thermo Fisher is investing heavily in AI‑enabled instrumentation and connectivity, positioning itself to capture the accelerating adoption of automated, data‑rich platforms. While supply‑chain inflation remains a headwind, the company is actively mitigating costs through operational efficiencies and strategic sourcing, preserving margin integrity.

3. NewsRoom

Card image cap

Thermo Fisher Scientific Opens U.S. Flagship Bioprocess Design Center to Accelerate the Delivery of Life-changing Therapies

Apr -28

Source: businesswire.com

Card image cap

Thermo Fisher Scientific to Host Investor Day

Apr -28

Source: businesswire.com

Card image cap

Thermo Fisher to Sell Microbiology Business to Astorg

Apr -27

Source: wsj.com

Card image cap

Thermo Fisher to sell its microbiology business to Astorg for about $1.08 billion

Apr -27

Source: reuters.com

Card image cap

Thermo Fisher Scientific Signs Agreement to Sell its Microbiology Business to Astorg

Apr -27

Source: businesswire.com

Card image cap

TMO Fairly Valued by DCF at $478

Apr -27

Source: gurufocus.com

Card image cap

Comerica Bank Cuts Position in Thermo Fisher Scientific Inc. $TMO

Apr -27

Source: defenseworld.net

Card image cap

Concurrent Investment Advisors LLC Has $6.14 Million Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Apr -27

Source: defenseworld.net

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (5.30%)

6. Segments

Laboratory Products and Biopharma Services

Expected Growth: 5.5%

Thermo Fisher Scientific Inc.'s Laboratory Products and Biopharma Services segment growth of 5.5% is driven by increasing demand for life sciences research, biopharmaceutical production, and COVID-19 related testing. The company's diversified portfolio, innovative products, and strategic acquisitions have enabled it to capitalize on these trends, leading to revenue growth.

Analytical Instruments

Expected Growth: 4.5%

Thermo Fisher Scientific's analytical instruments segment growth of 4.5% is driven by increasing demand for laboratory equipment, expanding applications in life sciences and pharmaceuticals, and strategic acquisitions. The company's strong portfolio of products, including chromatography and mass spectrometry systems, has enabled it to capitalize on emerging trends and gain market share.

Life Sciences Solutions

Expected Growth: 5.0%

Life Sciences Solutions' 5.0% growth is driven by increasing demand for biopharmaceuticals, government funding for research, and a robust pipeline of new therapies. Additionally, Thermo Fisher's strategic acquisitions and innovative product offerings, such as its genetic sequencing and cell therapy solutions, have expanded its market share and capabilities, fueling growth in this segment.

Specialty Diagnostics

Expected Growth: 4.0%

The Specialty Diagnostics segment of Thermo Fisher Scientific Inc. is driven by growing demand for rare disease testing, personalized medicine, and advanced diagnostic technologies. Its 4.0% growth is fueled by increased adoption of genetic testing, expanding applications in oncology, and strategic acquisitions, enabling the company to capitalize on emerging trends in precision medicine.

Eliminations

Expected Growth: 0.0%

The eliminations from Thermo Fisher Scientific Inc. show 0.0% growth, indicating a stable and neutral impact on the company's financials. This suggests that inter-segment transactions and eliminations have remained consistent, with no significant changes in business operations or structure. This stability allows for a focus on organic growth drivers within the company's core segments.

7. Detailed Products

Laboratory Instruments

Thermo Fisher Scientific offers a wide range of laboratory instruments, including spectrophotometers, chromatography systems, and microscopes, designed to support various scientific research and testing applications.

Life Science Reagents

Thermo Fisher Scientific provides a broad portfolio of life science reagents, including antibodies, proteins, and nucleic acid-based products, used in various biological research and diagnostic applications.

Biosciences

Thermo Fisher Scientific offers a range of biosciences products, including gene expression analysis, protein analysis, and cell culture media, used in various biological research and diagnostic applications.

Pharmaceutical Services

Thermo Fisher Scientific provides pharmaceutical services, including contract research, development, and manufacturing, to support the development and commercialization of pharmaceutical products.

Laboratory Consumables

Thermo Fisher Scientific offers a wide range of laboratory consumables, including pipette tips, microplates, and laboratory plastics, used in various scientific research and testing applications.

Bioproduction

Thermo Fisher Scientific provides bioproduction products and services, including cell culture media, bioreactors, and downstream processing, used in the development and manufacturing of biologics and vaccines.

Software and Informatics

Thermo Fisher Scientific offers a range of software and informatics solutions, including laboratory information management systems, electronic laboratory notebooks, and bioinformatics tools, used in various scientific research and testing applications.

8. Thermo Fisher Scientific Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Thermo Fisher Scientific Inc. has a moderate threat of substitutes due to the presence of alternative products and services in the life sciences and biotechnology industries.

Bargaining Power Of Customers

Thermo Fisher Scientific Inc. has a low bargaining power of customers due to its strong brand reputation and diversified customer base.

Bargaining Power Of Suppliers

Thermo Fisher Scientific Inc. has a moderate bargaining power of suppliers due to its dependence on a few key suppliers for raw materials and components.

Threat Of New Entrants

Thermo Fisher Scientific Inc. has a low threat of new entrants due to the high barriers to entry in the life sciences and biotechnology industries, including significant capital requirements and regulatory hurdles.

Intensity Of Rivalry

Thermo Fisher Scientific Inc. operates in a highly competitive industry with several established players, leading to a high intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 42.77%
Debt Cost 4.12%
Equity Weight 57.23%
Equity Cost 7.91%
WACC 6.29%
Leverage 74.73%

11. Quality Control: Thermo Fisher Scientific Inc. passed 5 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Agilent Technologies

A-Score: 5.2/10

Value: 2.0

Growth: 6.1

Quality: 7.8

Yield: 1.0

Momentum: 7.0

Volatility: 7.3

1-Year Total Return ->

View Full Report
Stock-Card
Mettler-Toledo

A-Score: 5.2/10

Value: 3.0

Growth: 6.3

Quality: 7.1

Yield: 0.0

Momentum: 7.5

Volatility: 7.3

1-Year Total Return ->

View Full Report
Stock-Card
IDEXX Laboratories

A-Score: 5.1/10

Value: 0.0

Growth: 7.2

Quality: 8.6

Yield: 0.0

Momentum: 9.5

Volatility: 5.0

1-Year Total Return ->

View Full Report
Stock-Card
IQVIA

A-Score: 4.8/10

Value: 3.5

Growth: 6.9

Quality: 5.5

Yield: 0.0

Momentum: 7.0

Volatility: 6.0

1-Year Total Return ->

View Full Report
Stock-Card
Thermo Fisher

A-Score: 4.8/10

Value: 1.7

Growth: 6.1

Quality: 6.2

Yield: 0.0

Momentum: 7.0

Volatility: 7.7

1-Year Total Return ->

View Full Report
Stock-Card
Danaher

A-Score: 4.3/10

Value: 1.7

Growth: 3.9

Quality: 6.8

Yield: 1.0

Momentum: 5.0

Volatility: 7.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

466.26$

Current Price

466.26$

Potential

-0.00%

Expected Cash-Flows